MedPath

S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer

Phase 3
Conditions
Head and Neck Cancer
Registration Number
NCT00336947
Lead Sponsor
Yokohama City University
Brief Summary

RATIONALE: Drugs used in chemotherapy, such as S-1 and tegafur-uracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving S-1 or tegafur-uracil after surgery, chemotherapy, biological therapy, and/or radiation therapy may kill any remaining tumor cells. It is not yet known whether S-1 is more effective than tegafur-uracil in treating head and neck cancer.

PURPOSE: This randomized phase III trial is studying S-1 to see how well it works compared with tegafur-uracil in treating patients with previously treated stage III or stage IV head and neck cancer.

Detailed Description

OBJECTIVES:

* Compare the disease-free survival rate in patients with definitively treated stage III or IV squamous cell carcinoma of the head and neck treated with adjuvant chemotherapy comprising S-1 vs tegafur-uracil (UFT).

OUTLINE: This is a randomized, controlled, multicenter study. Patients are stratified according to primary site, disease stage, type of prior definitive treatment, and participating center. Patients are randomized to 1 of 2 treatment arms.

* Arm I: Patients receive oral S-1 once daily on days 1-14. Courses repeat every 21 days for 1 year in the absence of disease progression or unacceptable toxicity.

* Arm II:Patients receive oral tegafur-uracil (UFT) once daily on days 1-21. Courses repeat every 21 days for 1 year in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 500 patients will be accrued for this study.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
500
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Disease-free survival
Secondary Outcome Measures
NameTimeMethod
Relapse-free survival
Overall survival
Adverse effects

Trial Locations

Locations (48)

National Hospital Organization - Himeji Medical Center

🇯🇵

Himeji-shi, Hyogo, Japan

Fujita Health University

🇯🇵

Toyoake, Aichi, Japan

Mie University Graduate School of Medicine

🇯🇵

Tsu, Mie, Japan

Yokohama City University

🇯🇵

Yokohama, Kanagawa, Japan

Iwate Medical University Hospital

🇯🇵

Morioka-shi, Iwate, Japan

Wakayama Medical University

🇯🇵

Wakayama-shi, Wakayama, Japan

Nippon Medical School

🇯🇵

Tokyo, Japan

Tokyo Medical University

🇯🇵

Tokyo, Japan

Aichi Cancer Center

🇯🇵

Nagoya, Aichi, Japan

Ehime University Hospital

🇯🇵

Toon, Ehime, Japan

National Kyushu Cancer Center

🇯🇵

Fukuoka-shi, Fukuoka, Japan

Hokkaido University Hospital

🇯🇵

Sapporo, Hokkaido, Japan

Kinki University School of Medicine

🇯🇵

Osakasayama, Osaka, Japan

Hamamatsu University School of Medicine

🇯🇵

Hamamatsu, Shizuoka, Japan

University of Fukui Hospital

🇯🇵

Fukui, Japan

Fukushima Medical University Hospital

🇯🇵

Fukushima, Japan

Juntendo University School of Medicine

🇯🇵

Tokyo, Japan

National Tokyo Medical Center

🇯🇵

Menguro-ku, Tokyo, Japan

Hyogo Cancer Center

🇯🇵

Akashi City, Hyogo, Japan

Kagoshima City Hospital

🇯🇵

Kagoshima City, Kagoshima, Japan

Kawasaki Medical School

🇯🇵

Kurashiki, Okayama, Japan

Saiseikai Utsunomiya Hospital

🇯🇵

Utsunomiya, Tochigi, Japan

Osaka General Medical Center

🇯🇵

Osaka, Japan

Osaka City University

🇯🇵

Osaka, Japan

Kyorin University School of Medicine - Mitaka Campus

🇯🇵

Mitaka-shi, Tokyo, Japan

Akita University Hospital

🇯🇵

Akita City, Akita, Japan

Gunma University Graduate School of Medicine

🇯🇵

Maebashi, Gunma, Japan

Tokyo Dental College Ichikawa General Hospital

🇯🇵

Ichikawa, Chiba, Japan

Gifu University Graduate School of Medicine

🇯🇵

Gifu-shi, Gifu, Japan

Kanazawa Medical University

🇯🇵

Kanazawa, Ishikawa, Japan

Yokohama Rosai Hospital

🇯🇵

Yokohama, Kanagawa, Japan

Kumamoto University Medical School

🇯🇵

Kumamoto City, Kumamoto, Japan

Tohoku University Graduate School of Medicine

🇯🇵

Sendai, Miyagi, Japan

Tenri Hospital

🇯🇵

Tenri, Nara, Japan

Shimane University Hospital

🇯🇵

Izumo, Shimane, Japan

Seirei Hamamatsu General Hospital

🇯🇵

Hamamatsu, Shizuoka, Japan

Tottori University Hospital

🇯🇵

Yonago-shi, Tottori, Japan

Interdiciplinary Graduate School of Medicine and Engineering

🇯🇵

Yamanashi, Yamagata, Japan

Cancer Institute Hospital of Japanese Foundation for Cancer Research

🇯🇵

Tokyo, Japan

Miyazaki Medical College University of Miyazaki

🇯🇵

Miyazaki-gun, Miyazaki, Japan

Niigata Prefectural Central Hospital

🇯🇵

Joetsu, Niigata, Japan

Tokyo Medical University Hachioji Medical Center

🇯🇵

Hachioji, Tokyo, Japan

Ome Municipal General Hospital

🇯🇵

Ome-shi, Tokyo, Japan

Kagoshima University

🇯🇵

Kagoshima, Japan

Saitama Cancer Center

🇯🇵

Saitama, Japan

Tokyo Medical and Dental University

🇯🇵

Tokyo, Japan

Keio University School of Medicine

🇯🇵

Tokyo, Japan

International Medical Center of Japan

🇯🇵

Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath